Active, not recruitingPhase 3NCT04273945

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Actelion
Principal Investigator
Actelion Clinical Trials
Actelion
Intervention
Macitentan 10 mg(drug)
Enrollment
935 enrolled
Eligibility
18 years · All sexes
Timeline
20202029

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04273945 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials